203 related articles for article (PubMed ID: 33199729)
61. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response.
Yebra M; Bhargava S; Kumar A; Burgoyne AM; Tang CM; Yoon H; Banerjee S; Aguilera J; Cordes T; Sheth V; Noh S; Ustoy R; Li S; Advani SJ; Corless CL; Heinrich MC; Kurzrock R; Lippman SM; Fanta PT; Harismendy O; Metallo C; Sicklick JK
Clin Cancer Res; 2022 Jan; 28(1):187-200. PubMed ID: 34426440
[TBL] [Abstract][Full Text] [Related]
62. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
63. Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA.
Mayr P; Märkl B; Agaimy A; Kriening B; Dintner S; Schenkirsch G; Schneider-Stock R
Langenbecks Arch Surg; 2019 Aug; 404(5):605-613. PubMed ID: 30877378
[TBL] [Abstract][Full Text] [Related]
64. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.
Miettinen M; Wang ZF; Sarlomo-Rikala M; Osuch C; Rutkowski P; Lasota J
Am J Surg Pathol; 2011 Nov; 35(11):1712-21. PubMed ID: 21997692
[TBL] [Abstract][Full Text] [Related]
65. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
66. GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases.
Miettinen M; Felisiak-Golabek A; Wang Z; Inaguma S; Lasota J
Am J Surg Pathol; 2017 May; 41(5):577-585. PubMed ID: 28288036
[TBL] [Abstract][Full Text] [Related]
67. Molecular and morphological correlation in gastrointestinal stromal tumours (GISTs): an update and primer.
Chetty R; Serra S
J Clin Pathol; 2016 Sep; 69(9):754-60. PubMed ID: 27317811
[TBL] [Abstract][Full Text] [Related]
68. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.
Schaefer IM; Wang Y; Liang CW; Bahri N; Quattrone A; Doyle L; Mariño-Enríquez A; Lauria A; Zhu M; Debiec-Rychter M; Grunewald S; Hechtman JF; Dufresne A; Antonescu CR; Beadling C; Sicinska ET; van de Rijn M; Demetri GD; Ladanyi M; Corless CL; Heinrich MC; Raut CP; Bauer S; Fletcher JA
Nat Commun; 2017 Mar; 8():14674. PubMed ID: 28270683
[TBL] [Abstract][Full Text] [Related]
69. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
70. Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs).
Miwa S; Nakajima T; Murai Y; Takano Y; Sugiyama T
J Gastroenterol; 2008; 43(7):531-7. PubMed ID: 18648740
[TBL] [Abstract][Full Text] [Related]
71. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors.
Wagner AJ; Remillard SP; Zhang YX; Doyle LA; George S; Hornick JL
Mod Pathol; 2013 Feb; 26(2):289-94. PubMed ID: 22955521
[TBL] [Abstract][Full Text] [Related]
72. Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.
Belinsky MG; Rink L; Cai KQ; Capuzzi SJ; Hoang Y; Chien J; Godwin AK; von Mehren M
BMC Cancer; 2015 Nov; 15():887. PubMed ID: 26555092
[TBL] [Abstract][Full Text] [Related]
73. Expression of podoplanin is a rare event in sporadic gastrointestinal stromal tumors and does not influence prognosis.
Schoppmann SF; Berghoff AS; Jesch B; Zacherl J; Nirtl N; Jomrich G; Maroske F; Streubel B; Mesteri I; Birner P
Future Oncol; 2012 Jul; 8(7):859-66. PubMed ID: 22830405
[TBL] [Abstract][Full Text] [Related]
74. Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors.
Zhao Y; Feng F; Guo QH; Wang YP; Zhao R
World J Gastroenterol; 2020 Sep; 26(34):5074-5089. PubMed ID: 32982110
[TBL] [Abstract][Full Text] [Related]
75. Morphological, immunohistochemical, and genetic analyses of epithelioid gastrointestinal stromal tumors.
Shi J; Sun K; Kong F; Shen D
Ann Diagn Pathol; 2023 Dec; 67():152208. PubMed ID: 37696133
[TBL] [Abstract][Full Text] [Related]
76. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.
Perrone F; Tamborini E; Dagrada GP; Colombo F; Bonadiman L; Albertini V; Lagonigro MS; Gabanti E; Caramuta S; Greco A; Torre GD; Gronchi A; Pierotti MA; Pilotti S
Cancer; 2005 Jul; 104(1):159-69. PubMed ID: 15929122
[TBL] [Abstract][Full Text] [Related]
77. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
78. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
Joensuu H; Rutkowski P; Nishida T; Steigen SE; Brabec P; Plank L; Nilsson B; Braconi C; Bordoni A; Magnusson MK; Sufliarsky J; Federico M; Jonasson JG; Hostein I; Bringuier PP; Emile JF
J Clin Oncol; 2015 Feb; 33(6):634-42. PubMed ID: 25605837
[TBL] [Abstract][Full Text] [Related]
79. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.
Janeway KA; Zhu MJ; Barretina J; Perez-Atayde A; Demetri GD; Fletcher JA
Int J Cancer; 2010 Dec; 127(11):2718-22. PubMed ID: 20162573
[TBL] [Abstract][Full Text] [Related]
80. GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors.
Lee EJ; Kang G; Kang SW; Jang KT; Lee J; Park JO; Park CK; Sohn TS; Kim S; Kim KM
PLoS One; 2013; 8(10):e77219. PubMed ID: 24124608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
